Edition:
United States

Sanofi SA (SASY.PA)

SASY.PA on Paris Stock Exchange

75.16EUR
24 May 2019
Change (% chg)

€0.26 (+0.35%)
Prev Close
€74.90
Open
€75.18
Day's High
€75.51
Day's Low
€74.95
Volume
1,806,876
Avg. Vol
2,351,250
52-wk High
€80.44
52-wk Low
€64.45

About

Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. Its segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality... (more)

Overall

Beta: 0.93
Market Cap(Mil.): €108,903.00
Shares Outstanding(Mil.): 1,262.50
Dividend: 2.96
Yield (%): 3.43

Financials

  SASY.PA Industry Sector
P/E (TTM): 23.32 29.30 32.55
EPS (TTM): 3.70 -- --
ROI: 5.69 14.23 13.82
ROE: 8.50 15.46 15.25

Race for Italian chemicals firm ICE attracts four buyout funds: sources

LONDON/MILAN/FRANKFURT Four private equity firms are looking to submit final bids for Italian chemicals firm Industria Chimica Emiliana (ICE) in a deal valued at about 600 million euros ($673 million), sources familiar with the matter told Reuters.

May 15 2019

Race for Italian chemicals firm ICE attracts four buyout funds - sources

LONDON/MILAN/FRANKFURT, May 15 Four private equity firms are looking to submit final bids for Italian chemicals firm Industria Chimica Emiliana (ICE) in a deal valued at about 600 million euros ($673 million), sources familiar with the matter told Reuters.

May 15 2019

RPT-ANALYSIS-Half-time: Europe Inc scores to avert Q1 disaster, hopes of a rebound rise

(Repeats story for wider distribution, no changes to text) * Industrials shine with 5 percent positive surprise * Companies cite China as a positive rather than a negative * Technology and healthcare also showing strength * Companies point to second half rebound By Helen Reid and Thyagaraju Adinarayan LONDON, May 2 European investors breathed a sigh of relief as more than half the region's major companies reported first-quarter earnings above market expectat

May 03 2019

Half-time: Europe Inc scores to avert first-quarter disaster, hopes of a rebound rise

LONDON European investors breathed a sigh of relief as more than half the region's major companies reported first-quarter earnings above market expectations, even if the bar was set very low ahead of results season, underscoring hopes the worst is behind Europe Inc.

May 02 2019

ANALYSIS-Half-time: Europe Inc scores to avert Q1 disaster, hopes of a rebound rise

* Industrials shine with 5 percent positive surprise * Companies cite China as a positive rather than a negative * Technology and healthcare also showing strength * Companies point to second half rebound By Helen Reid and Thyagaraju Adinarayan LONDON, May 2 European investors breathed a sigh of relief as more than half the region's major companies reported first-quarter earnings above market expectations, even if the bar was set very low ahead of results seas

May 02 2019

FDA approves expanded label for Regeneron/Sanofi's cholesterol drug

The U.S. Food and Drug Administration on Friday approved Regeneron Pharmaceuticals Inc's cholesterol drug Praluent as a treatment to cut the risk of heart attacks, stroke and other major cardiovascular events.

Apr 26 2019

UPDATE 1-U.S. FDA approves expanded label for Regeneron/Sanofi's cholesterol drug

April 26 The U.S. Food and Drug Administration on Friday approved Regeneron Pharmaceuticals Inc's cholesterol drug Praluent as a treatment to cut the risk of heart attacks, stroke and other major cardiovascular events.

Apr 26 2019

UPDATE 3-European shares get a lift from strong earnings, U.S. GDP

April 26 European shares finished higher on Friday as some strong earnings and data showing U.S. economic growth in the first-quarter beat expectations helped cut losses from earlier in the session.

Apr 26 2019

Genzyme and vaccines push up Sanofi's first quarter results

PARIS Sanofi upheld a long-awaited return to growth on Friday with higher profits and revenues for the first quarter, once again led by a stellar sales increase at its rare diseases Genzyme unit.

Apr 26 2019

Earnings vs. Estimates